4 Reasons Pfizer Remains A Buy Today

Posted On September 19, 2016 1:06 am

Pfizer may have lagged some of its bigger rivals over the past year, but that doesn’t mean that it isn’t a great long-term dividend growth stock. Find our 4 reasons why Wall Street is wrong for punishing Pfizer for its last two failed mega-mergers, and how you can benefit from the market’s short sightedness.

Continue Reading Here

About author

Dividend Sensei
Dividend Sensei

I'm an Army veteran and former energy dividend writer for The Motley Fool. I'm a proud co-founder of Wide Moat Research, Dividend Kings, and the Intelligent Dividend Investor. My work can be found on Seeking Alpha, Dividend Kings, iREIT, and the Intelligent Dividend Investor. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams and enrich their lives. With 24 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams and achieving long-term financial goals.

Related Articles

Leave a reply

Your email address will not be published. Required fields are marked *